Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Feces

ABSTRACT: Effects of Fecal Microbiota Transplantation on Bile Acid Malabsorption in Inflammatory Bowel Disease

PROVIDER: PRJNA1114418 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR29139500_1.fastq.gz	Fastqsanger.gz
	SRR29139500_2.fastq.gz	Fastqsanger.gz
	SRR29139600_1.fastq.gz	Fastqsanger.gz
	SRR29139600_2.fastq.gz	Fastqsanger.gz
	SRR29139501_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 340

Similar Datasets

The Pathogenesis of Chronic Diarrhoea After Treatment for Cancer in Cecum and the Ascending Colon

Project description:Many patients suffer from chronic diarrhoea after surgical treatment for cancer in the right side of the colon. The investigators’ main hypothesis is that colon cancer patients with chronic diarrhoea have a higher risk of bile acid malabsorption compared with colon cancer patients without diarrhoea. The investigators also expect that a part of the cases of bile acid malabsorption is caused by underlying bacterial overgrowth in the small bowel. The investigators assume that patients with severe bile acid malabsorption have a lower value of FGF19 in the blood compared to patients with moderate or none bile acid malabsorption. Furthermore, it is assumed that patients with chronic diarrhoea and documented bile acid malabsorption after surgical treatment for right-sided colon cancer will get improved bowel function when treated with a bile acid binder, or antibiotics in case of bacterial overgrowth.

| 2309640 | ecrin-mdr-crc

Homo sapiens

Project description:Fecal microbiota transplantation in pediatric inflammatory bowel disease

| PRJNA380419 | ENA

gut metagenome

Project description:Fecal Microbiota Transplantation in a dog with inflammatory bowel disease

| PRJDB10694 | ENA

16s rDNA sequencing of feces from C9orf72 loss of function mice

Project description:We report the sequencing of bacterial species across four environments in which C9orf72 loss of function mice were studied as well as mice that received fecal transplantation. Our study elucidates bacterial communities that associate with pro-inflammatory or pro-survival outcomes in this model of ALS/FTD with features of autoimmunity and systemic and neural inflammation.

2020-03-24 | GSE147325 | GEO

Metagenomic and 16S amplicon reads of subjects with or without Irritable Bowel Syndrome (IBS).

Project description:Differences in Fecal Microbiomes and Metabolomes of People With vs Without Irritable Bowel Syndrome and Bile Acid Malabsorption

| PRJEB42304 | ENA

Impact of fecal microbiota transplantation (FMT) in 3 days-ABX-treated recipient mice using feces from 6 NSCLC patients at diagnosis.

Project description:This study aimed to analyze changes in gut microbiota composition in mice after transplantation of fecal microbiota (FMT, N = 6) from the feces of NSCLC patients by analyzing fecal content using 16S rRNA sequencing, 10 days after transplantation. Specific-pathogen-free (SPF) mice were used for each experiments (N=4) as controls.

2023-07-01 | E-MTAB-12812 | biostudies-arrayexpress

human gut microbiome

Project description:The Intestinal Microbiome in Children with Inflammatory Bowel Disease and Lactose Malabsorption

| PRJNA1062375 | ENA

Intestinal tumor expression data from Apcmin/+ mice gavaged by feces from healthy controls or colorectal cancer patients

Project description:Colorectal cancer (CRC) is closely related to gut dysbiosis. We investigated the effects of imbalanced gut microbiota on the progression of intestinal adenoma in Apcmin/+ mice model using fecal microbiota transplantation (FMT). Administration of feces from CRC patients increased tumor proliferation and decreased apoptosis in tumor cells. Abnormal expression of genes related to Wnt-protein binding and lipid metabolic process was observed.

2019-09-16 | GSE136682 | GEO

Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice

Project description:Abstract: Interruption of bile acid recirculation through inhibition of the apical sodium-dependent bile acid transporter (ASBT) is a promising strategy to alleviate hepatic cholesterol accumulation in non-alcoholic steatohepatitis, and improve the metabolic aspects of the disease. Putative disease-attenuating effects of the ASBT inhibitor volixibat (5, 15, and 30 mg/kg) were investigated in high-fat diet (HFD)-fed Ldlr-/-.Leiden mice over 24 weeks. Plasma and fecal bile acid levels, plasma insulin, lipids, and liver enzymes were monitored. Final analyses included liver histology, intrahepatic lipids, mesenteric white adipose tissue mass, and liver gene profiling. Consistent with its mechanism of action, volixibat significantly increased total bile acid excretion. At the highest dose, volixibat significantly attenuated the HFD-induced increase in hepatocyte hypertrophy, hepatic triglyceride and cholesteryl ester levels, and mesenteric white adipose tissue deposition, while total plasma bile acid levels remained constant. Non-alcoholic fatty liver disease activity score was significantly lower in volixibat-treated mice than in the HFD controls. Gene profiling showed that volixibat reversed the inhibitory effect of the HFD on metabolic master regulators, including peroxisome proliferator-activated receptor-γ coactivator-1β, insulin receptor, and sterol regulatory element-binding transcription factor 2. Volixibat may have beneficial effects on physiological and metabolic aspects of non-alcoholic steatohepatitis pathophysiology.

2019-06-07 | GSE129306 | GEO

Fecal protein changes in different colorectal diseases

Project description:We examined fecal proteins from normal subjects (n=6), patients with inflammatory bowel disease (n=8), patients with colorectal adenoma (n=8), and patients with colorectal cancer (n=14) in the hope of identifying novel fecal protein markers that could be used to identify colorectal diseases.

2022-12-22 | PXD039089 |

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data